Filtered By:
Therapy: Neoadjuvant Therapy

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 10587 results found since Jan 2013.

Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.
CONCLUSIONS: BPE of the contralateral breast is associated with breast cancer in several aspects, therefore it has been proposed as a tool to refine breast cancer decision-making process. ADVANCES IN KNOWLEDGE: additional researches with standardized BPE assessment are needed to translate this emerging biomarker into clinical practice in the era of personalized medicine. PMID: 33035073 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - October 9, 2020 Category: Radiology Authors: Rella R, Contegiacomo A, Bufi E, Mercogliano S, Belli P, Manfredi R Tags: Br J Radiol Source Type: research

Platinum-based chemotherapy for early triple-negative breast cancer
CONCLUSIONS: Platinum-based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long-term outcomes of DFS and OS in early TNBC, with no evidence of differences by subgroup. This was at the cost of more frequent chemotherapy delays and dose reductions, and greater haematological toxicity, though serious adverse events including neuropathy, febrile neutropenia or treatment-related death were not increased. These findings support the use of platinum-based chemotherapy for people with early TNBC. The optimal dose and regimen are not defined by this analysis, but there is a suggestion that similar rel...
Source: Cochrane Database of Systematic Reviews - September 8, 2023 Category: General Medicine Authors: Sofia Re Mason Melina L Willson Sam J Egger Jane Beith Rachel F Dear Annabel Goodwin Source Type: research

Growth factors and gastrointestinal anastomotic healing
Conclusions: Future research should focus on adequate sustained but limited drug delivery. Undesired side effects, such as formation of strictures, development of peritoneal adhesions, and potential induction of malignancies, have to be reflected. Although growth factor application is currently far from clinical routine in gastrointestinal surgery, it might find application in selected patients at risk for impaired anastomotic healing, such as patients with long-time steroid therapy, immunosuppressives, inflammatory disorders, sepsis, hemodynamic shock, malnutrition, or neoadjuvant radiochemotherapy.
Source: Journal of Surgical Research - October 28, 2013 Category: Surgery Authors: Emile Rijcken, Larissa Sachs, Thomas Fuchs, Hans-Ullrich Spiegel, Philipp-Alexander Neumann Tags: Research Review Source Type: research

Cancers, Vol. 13, Pages 6088: Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy
ert D. Windhorst Jacobus Burggraaf Alexander L. Vahrmeijer J. Sven D. Mieog Background: Despite recent advances in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC), overall survival remains poor with a 5-year cumulative survival of approximately 10%. Neoadjuvant (chemo- and/or radio-) therapy is increasingly incorporated in treatment strategies for patients with (borderline) resectable and locally advanced disease. Neoadjuvant therapy aims to improve radical resection rates by reducing tumor mass and (partial) encasement of important vascular structures, as well as eradicating occult micrometas...
Source: Cancers - December 2, 2021 Category: Cancer & Oncology Authors: Martijn A. van Dam Floris A. Vuijk Judith A. Stibbe Ruben D. Houvast Saskia A. C. Luelmo Stijn Crobach Shirin Shahbazi Feshtali Lioe-Fee de Geus-Oei Bert A. Bonsing Cornelis F. M. Sier Peter J. K. Kuppen Rutger-Jan Swijnenburg Albert D. Windhorst Jacobus Tags: Review Source Type: research

Effectiveness and safety of adjuvant chemotherapy compared to neoadjuvant chemotherapy in patients with penile cancer and positive lymph nodes regarding overall survival and free disease survival: a systematic review and meta-analysis
CONCLUSIONS: There were no differences when comparing adjuvant vs. neoadjuvant chemotherapy or adjuvant vs. no intervention chemotherapy. We conclude that progression-free survival had a better response with adjuvant chemotherapy when compared with neoadjuvant therapy. We suggest more studies with adequate design to offer a stronger recommendation.PMID:35307290 | DOI:10.1016/j.urolonc.2022.02.014
Source: Urologic Oncology - March 21, 2022 Category: Urology & Nephrology Authors: Juan Fernando Paz Rojas Carlos A Ballestas Almario Herney Andr és García-Perdomo Source Type: research

Platinum-based chemotherapy for early triple-negative breast cancer
CONCLUSIONS: Platinum-based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long-term outcomes of DFS and OS in early TNBC, with no evidence of differences by subgroup. This was at the cost of more frequent chemotherapy delays and dose reductions, and greater haematological toxicity, though serious adverse events including neuropathy, febrile neutropenia or treatment-related death were not increased. These findings support the use of platinum-based chemotherapy for people with early TNBC. The optimal dose and regimen are not defined by this analysis, but there is a suggestion that similar rel...
Source: Cancer Control - September 8, 2023 Category: Cancer & Oncology Authors: Sofia Re Mason Melina L Willson Sam J Egger Jane Beith Rachel F Dear Annabel Goodwin Source Type: research

Assessment of pathological response in breast cancer after neoadjuvant chemotherapy: standardization of adapted protocol
We present a proposal for the evaluation of pathological response in breast tumors after neoadjuvant chemotherapy. Based on Symmans et al. study, it consists in a protocol adapted to our routine pathological examination of surgical specimens.
Source: Jornal Brasileiro de Patologia e Medicina Laboratorial - February 23, 2013 Category: Pathology Source Type: research

Immunohistochemical expression of Ki67, EGFR and TRKC and their correlation with prognostic factors in medulloblastoma
Conclusion: The immunoexpression of TRKC might be considered a biomarker related to tumors with better prognosis in patients with medulloblastoma, contributing to better risk groups' stratification. Introdução: O meduloblastoma é o tumor maligno do cerebelo com prognóstico reservado. Seu tratamento baseia-se somente em critérios clínicos, como os grupos de risco que levam em consideração apenas idade, extensão de ressecção, recidiva e metástase. Objetivo: Avaliar uma possível relação entre a imunoexpressão de biomarcadores (Ki67, receptor de neurotrofina-3 [TRKC], epidermal growth factor receptor [EGFR], B...
Source: Jornal Brasileiro de Patologia e Medicina Laboratorial - October 7, 2014 Category: Pathology Source Type: research